In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savoring Sabex: Sandoz' Play in Injectable Generics

Executive Summary

Sandoz, the generics unit of Novartis, is buying Sabex, a Canadian maker of injectable generics for $565 million cash, marking its entree into an attractive sector of generics and also the Canadian generics market. The 6X sales multiple aimed to dissuade Sabex owners from shopping for another buyer. Novartis is the only big pharma company to succeed in generics. Its play is opportunistic, but a secondary effect is a free-market response to pressure on big pharma to make drugs more affordable.
Advertisement

Related Content

Teva/Ivax: Generics' Answer to Big Pharma
Teva/Ivax: Generics' Answer to Big Pharma
Novartis/Hexal: Generic Consolidation, and More
Novartis/Hexal: Generic Consolidation, and More
Authorized Generics: Band-Aid or Strategy?
Ranbaxy & Lilly: Flexibility in Building a Generics Business
Generic Update: Brand-Name Companies Vs. Independents

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel